Pharvaris director Meeker discloses equity holdings

Q: What does the Pharvaris (PHVS) Form 3 filing by David P. Meeker show?

The Form 3 shows that director David P. Meeker reports his existing equity holdings in Pharvaris N.V., including common stock, stock options and restricted stock units. It is an initial statement of beneficial ownership, not a report of new share purchases or sales.

Q: How many Pharvaris (PHVS) common shares does David P. Meeker hold?

David P. Meeker directly holds 65,167 shares of Pharvaris common stock according to the Form 3. These shares are reported as non-derivative securities, separate from his stock options and restricted stock units, and reflect his direct ownership position as of the filing date.

Q: What stock options does David P. Meeker report in the Pharvaris (PHVS) Form 3?

Meeker reports several Stock Option (Right to Buy) awards over Pharvaris common stock, with exercise prices such as $7.89, $8.05, $16.05, $18.14, $22.31 and $28.00, and expiration dates ranging from 2031 through 2036, all held directly.

Q: What restricted stock units (RSUs) does David P. Meeker hold in Pharvaris (PHVS)?

The filing notes outstanding restricted stock units granted under Pharvaris’s equity plan, which settle in common stock. This includes 5,500 RSUs from an award granted on March 3, 2026, scheduled to vest 100% on March 3, 2027, as described in the footnotes.

Q: Did David P. Meeker buy or sell Pharvaris (PHVS) shares in this Form 3?

The Form 3 does not report any buying or selling transactions. It lists holdings as of the reporting date: common stock, stock options and restricted stock units. All transaction entries are categorized as holdings, with no buy or sell codes or share amounts reported as trades.

Pharvaris N.V. director David P. Meeker reports his current equity holdings, including common shares, stock options and restricted stock units.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Pharvaris N.V. director David P. Meeker reports his current equity holdings, including common shares, stock options and restricted stock units. He holds 65,167 shares of Common Stock directly, as well as multiple stock option awards to buy additional shares at exercise prices ranging from $7.89 to $28.00 per share, with expirations between 2031 and 2036. The filing also notes outstanding restricted stock units, including 5,500 RSUs from an award granted on March 3, 2026 that will fully vest on March 3, 2027, settling in common stock.

Insider Trade Summary

7 transactions reported

Mixed 7 txns

Insider Meeker David P

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 164,000 contracts (Direct); Common Stock — 65,167 shares (Direct)

Footnotes (5)

F1. Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -5,500 RSUs from an award granted March 3, 2026 of which 100% will vest March 3, 2027.
F2. 100% of the option vest on the 12-month anniversary.
F3. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.
F4. 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.
F5. 25% of the option vested on January 1, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Pharvaris (PHVS) Form 3 filing by David P. Meeker show?

The Form 3 shows that director David P. Meeker reports his existing equity holdings in Pharvaris N.V., including common stock, stock options and restricted stock units. It is an initial statement of beneficial ownership, not a report of new share purchases or sales.

How many Pharvaris (PHVS) common shares does David P. Meeker hold?

David P. Meeker directly holds 65,167 shares of Pharvaris common stock according to the Form 3. These shares are reported as non-derivative securities, separate from his stock options and restricted stock units, and reflect his direct ownership position as of the filing date.

What stock options does David P. Meeker report in the Pharvaris (PHVS) Form 3?

Meeker reports several Stock Option (Right to Buy) awards over Pharvaris common stock, with exercise prices such as $7.89, $8.05, $16.05, $18.14, $22.31 and $28.00, and expiration dates ranging from 2031 through 2036, all held directly.

What restricted stock units (RSUs) does David P. Meeker hold in Pharvaris (PHVS)?

The filing notes outstanding restricted stock units granted under Pharvaris’s equity plan, which settle in common stock. This includes 5,500 RSUs from an award granted on March 3, 2026, scheduled to vest 100% on March 3, 2027, as described in the footnotes.

Did David P. Meeker buy or sell Pharvaris (PHVS) shares in this Form 3?

The Form 3 does not report any buying or selling transactions. It lists holdings as of the reporting date: common stock, stock options and restricted stock units. All transaction entries are categorized as holdings, with no buy or sell codes or share amounts reported as trades.

What are the key expiration dates for David P. Meeker’s Pharvaris (PHVS) stock options?

Meeker’s reported stock options over Pharvaris common stock have staggered expiration dates, including January 1, 2031, April 1, 2032, April 6, 2033, April 11, 2034, March 12, 2035 and March 3, 2036, reflecting long-dated equity incentives.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/18/2026 - 02:23 PM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Meeker David P

(Last)

(First)

(Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON

MASSACHUSETTS

02421

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	65,167⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	03/03/2027⁽²⁾	03/03/2036	Common Stock	16,500	$28	D
Stock Option (Right to Buy)	03/12/2026⁽²⁾	03/12/2035	Common Stock	15,000	$16.05	D
Stock Option (Right to Buy)	04/11/2025⁽²⁾	04/11/2034	Common Stock	14,000	$22.31	D
Stock Option (Right to Buy)	⁽³⁾	04/06/2033	Common Stock	21,000	$8.05	D
Stock Option (Right to Buy)	⁽⁴⁾	04/01/2032	Common Stock	17,500	$18.14	D
Stock Option (Right to Buy)	⁽⁵⁾	01/01/2031	Common Stock	80,000	$7.89	D

Explanation of Responses:

1. Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -5,500 RSUs from an award granted March 3, 2026 of which 100% will vest March 3, 2027.

2. 100% of the option vest on the 12-month anniversary.

3. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

4. 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.

5. 25% of the option vested on January 1, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

	/s/ Marnus Nel, Attorney-in-Fact for David Meeker	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR